A CDC advisory panel has recommended that the preservative thimerosal be dropped from flu vaccines, a largely symbolic move ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

A CDC advisory panel voted 5–1 to recommend only flu vaccines without the preservative thimerosal, a mercury-containing ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...